Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
22
04
2023
accepted:
07
09
2023
revised:
30
08
2023
medline:
26
9
2023
pubmed:
26
9
2023
entrez:
25
9
2023
Statut:
aheadofprint
Résumé
We conducted a prospective study aimed at investigating the prognostic value of the dynamic of a-GVHD progression from cutaneous to visceral involvement. In 108 consecutive patients who underwent allogeneic HSCT, we classified a-GVHD according to a "GHVD skin dynamic": 18/82 patients started Corticosteroid (CS) within 48 h (Group 1); 13/82 started CS within days 3-7 (Group 2); Group 3A (n 31) was defined when Skin GVHD Overall Grade 1, left untreated for 1 week, showed an increase in involved body surface area <5 %; Group 3B (n 20), was defined when Skin GVHD Overall Grade 1, left untreated at 1 week, had an increase in involved body surface area >5%. These four groups had distinctive 2-y OS. Patients could be then grouped into "poor risk" (Group 1 and Group 3B) and "good risk" (Group 2 and Group 3A). "Poor risk" had inferior OS in univariate and multivariate analysis, (HR 2.222; 95% CL: 1.017-4.855; p 0.04). Among the patients with skin-only Grade 1 GVHD, subgroup 3A had an OS of 75.1% versus 39.8% found in subgroup 3B (p = 0.03). The dynamic of skin GVHD may be used to classify a-GVHD and guide treatment in Overall Grade 1 skin-only GVHD.
Identifiants
pubmed: 37749188
doi: 10.1038/s41409-023-02107-z
pii: 10.1038/s41409-023-02107-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell trans-plantation. N Engl J Med. 2010;363:2091–101.
doi: 10.1056/NEJMoa1004383
pubmed: 21105791
pmcid: 3017343
Dalle JH, Giralt SA. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400–9. https://doi.org/10.1016/j.bbmt.2015.09.024 .
doi: 10.1016/j.bbmt.2015.09.024
Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, et al. Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:310–20. https://doi.org/10.1016/j.jtct.2022.03.015 .
doi: 10.1016/j.jtct.2022.03.015
pubmed: 35314376
pmcid: 9197865
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001 .
doi: 10.1097/00007890-197410000-00001
pubmed: 4153799
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Martino R, Romero P, Subirá M, et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. Bone Marrow Transplant.1999;24:283–7. https://doi.org/10.1038/sj.bmt.1701899
doi: 10.1038/sj.bmt.1701899
pubmed: 10455367
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–94. https://doi.org/10.1053/bbmt.2002.v8.pm12171485 .
doi: 10.1053/bbmt.2002.v8.pm12171485
pubmed: 12171485
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64. https://doi.org/10.1046/j.1365-2141.1997.1112925.x .
doi: 10.1046/j.1365-2141.1997.1112925.x
pubmed: 9217189
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–8. https://doi.org/10.1016/s1083-8791(03)00162-9 .
doi: 10.1016/s1083-8791(03)00162-9
pubmed: 12931120
Wallace AB. The exposure treatment of burns. Lancet. 1951;1:501–4. https://doi.org/10.1016/s0140-6736(51)91975-7 .
doi: 10.1016/s0140-6736(51)91975-7
pubmed: 14805109
Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Steroid treatment of acute graft-versus-host disease Grade I: a randomized trial. Haematologica. 2017;102:2125–33. https://doi.org/10.3324/haematol.2017.171157 .
doi: 10.3324/haematol.2017.171157
pubmed: 28971905
pmcid: 5709112
Gratwohl A, Brand R, Apperley J, Biezen AV, Bandini G, Devergie A, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT). Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–86. https://doi.org/10.1182/blood.V100.12.3877 .
doi: 10.1182/blood.V100.12.3877
pubmed: 12433695
Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63. https://doi.org/10.1016/j.bbmt.2012.04.005 .
doi: 10.1016/j.bbmt.2012.04.005
pubmed: 22510384
pmcid: 3404151
Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:1459–64. https://doi.org/10.1038/bmt.2012.45 .
doi: 10.1038/bmt.2012.45
pubmed: 22410750
Carpenter PA, Macmillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am. 2010;57:273–95. https://doi.org/10.1016/j.pcl.2009.11.007 .
doi: 10.1016/j.pcl.2009.11.007
pubmed: 20307721
pmcid: 3227683
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21:761–7. https://doi.org/10.1016/j.bbmt.2015.01.001 .
doi: 10.1016/j.bbmt.2015.01.001
pubmed: 25585275
pmcid: 4359643
McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126:113–20. https://doi.org/10.1182/blood-2015-03-636753 .
doi: 10.1182/blood-2015-03-636753
pubmed: 25987657
pmcid: 4492194
Leotta S, Sapienza G, Camuglia MG, Avola G, Marco AD, Moschetti G, et al. Preliminary results of a combined score based on sIL2-Rα and TIM-3 levels assayed early after hematopoietic transplantation. Front Immunol. 2020;10:3158. https://doi.org/10.3389/fimmu.2019.03158 .
doi: 10.3389/fimmu.2019.03158
pubmed: 32117211
pmcid: 7020780
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2:e89798. https://doi.org/10.1172/jci.insight.89798 .
doi: 10.1172/jci.insight.89798
pubmed: 28194439
pmcid: 5291735